Jim Cramer and our other experts discuss oil prices, bullish market signals and medical diagnostic plays.
Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.
When President Trump gave a speech on prescription drug pricing last week, many were disappointed pharmaceutical companies seemed to escape his wrath. The answer seems to be shame.
These three "strong buy" biotech stocks are primed for outsized growth in the next 12 months. Here's why.
What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle. Here's what that could mean for regulation of legal cannabis in the U.S.
Deals in biopharma slowed in 2017 for the third consecutive year. According to Intec Pharma CEO Jeffrey Meckler, just because volume is down doesn't mean it's out.
Alkermes has spent money lobbying and donating to elected officials, and in the White House opioid plan, it seems to have paid off, as opioid blocker Vivitrol becomes part of prison protocol.
Johnson & Johnson may be down, but don't count it out.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.